The CB1 Inverse Agonist AM251, but Not the CB1 Antagonist AM4113, Enhances Retention of Contextual Fear Conditioning in Rats [PDF]
The effects of CB1 antagonist/inverse agonists on the acquisition and consolidation of conditioned fear remain uncertain. Recent studies suggest that the CB1 antagonist/inverse agonist AM251 affects acquisition or consolidation of both contextual and discretely cued fear memories.
John D. Salamone +2 more
exaly +4 more sources
Discovery of Potent Dual PPARα Agonists/CB1 Ligands [PDF]
This letter describes the synthesis and in vitro and in vivo evaluation of dual ligands targeting the cannabinoid and peroxisome proliferator-activated receptors (PPAR). These compounds were obtained from fusing the pharmacophores of fibrates and the diarylpyrazole rimonabant, a cannabinoid receptor antagonist.
Pérez-Fernández, Ruth +9 more
openaire +3 more sources
Analysis of Tolerance and Behavioral/Physical Dependence during Chronic CB1 Agonist Treatment: Effects of CB1 Agonists, Antagonists, and Noncannabinoid Drugs [PDF]
Behavioral studies of chronic CB(1) receptor activation may provide a pharmacological approach to understanding efficacy-related differences among CB(1) ligands as well as mechanistic commonalities between cannabinoid and noncannabinoid drugs. In the present studies, the effects of CB(1) agonists [(6aR,10aR)-3-(1-adamantyl)-6,6,9-trimethyl-6a,7,10,10a ...
Rajeev I, Desai +5 more
openaire +2 more sources
Unique agonist-bound cannabinoid CB1 receptor conformations indicate agonist specificity in signaling [PDF]
Cannabinoid drugs differ in their rank order of potency to produce analgesia versus other central nervous system effects. We propose that these differences are due to unique agonist-bound cannabinoid CB1 receptor conformations that exhibit different affinities for individual subsets of intracellular signal transduction pathways.
Teodora, Georgieva +9 more
openaire +2 more sources
Improved cyclobutyl nabilone analogs as potent CB1 receptor agonists
In earlier work, we explored the SAR for the C3 side chain pharmacophore in the hexahydrocannabinol template represented by the drug nabilone, which resulted in the development of AM2389. In an effort for further optimization, we have merged features of nabilone and AM2389 and explored the C3 side chain with varying chain lengths and terminal ...
Ioannis P. Papanastasiou +13 more
openaire +3 more sources
Differentiation of CB1 cannabinoid agonists in rats
Results from GTPγS binding and other in vitro assays suggest that cannabinoid (CB) receptor agonists range in efficacy from partial to full agonists. The present studies compared the in vivo effects of
Carol Anne Paronis +7 more
openaire +1 more source
Two Janus Cannabinoids That Are Both CB2 Agonists and CB1 Antagonists [PDF]
The cannabinoid signaling system includes two G protein-coupled receptors, CB1 and CB2 These receptors are widely distributed throughout the body and have each been implicated in many physiologically important processes. Although the cannabinoid signaling system has therapeutic potential, the development of receptor-selective ligands remains a ...
Amey, Dhopeshwarkar +4 more
openaire +2 more sources
Cannabinoid CB1 receptor agonist ACEA alleviates brain ischemia/reperfusion injury via CB1–Drp1 pathway [PDF]
AbstractActivation of the cannabinoid CB1 receptor induces neuroprotection against brain ischemia/reperfusion injury (IRI); however, the mechanism is still unknown. In this study, we used oxygen-glucose deprivation/reoxygenation (OGD/R)-induced injury in neuronal cells and middle cerebral artery occlusion (MCAO)-induced brain IRI in rats to mimic ...
Yang, Shuai +8 more
openaire +2 more sources
CB1 inverse‐agonist antagonists (e.g., rimonabant) have behavioral effects that limit their clinical utility. Recent data suggest that CB1 neutral antagonists may not have rimonabant‐like effects, raising the possibility of improved clinical utility. The present studies were conducted to compare how inverse‐agonist antagonists (SR141716A, AM 6538) and ...
Brian D. Kangas +4 more
openaire +1 more source
Some effects of CB1 antagonists with inverse agonist and neutral biochemical properties [PDF]
The CB1 inverse agonist/antagonist SR141716A recently has been introduced for the management of obesity (rimonabant; Acomplia) and appears to have beneficial effects. However, its utility may be hampered in some individuals by adverse effects including nausea or emesis or by mood depression. The recent development of biochemically 'neutral' antagonists
Jack, Bergman +5 more
openaire +2 more sources

